2011
Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial.
Kelly C, Green M, Broglio K, Pusztai L, Thomas E, Brewster A, Valero V, Ibrahim N, Gonzalez-Angulo A, Booser D, Hunt K, Hortobagyi G, Buzdar A. Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial. Journal Of Clinical Oncology 2011, 29: 292-292. DOI: 10.1200/jco.2011.29.27_suppl.292.Peer-Reviewed Original ResearchTriple-negative breast cancerRelapse-free survivalPathological complete responseOperable triple-negative breast cancerOverall survivalSubgroup analysisBreast cancerWeeks x 4 cyclesRandomized phase III trialReceptor-negative breast cancerTriple receptor-negative breast cancerAddition of capecitabineProportion of patientsTiming of chemotherapyPhase III trialsUnplanned subgroup analysisNegative breast cancerMedian followPreoperative therapyDistant recurrenceIII trialsComplete responsePatientsD1-14Capecitabine
2007
Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes
Ueno N, Kim S, Symmans W, Detry M, Pusztai L, Sanchez L, Ishihara H, Hortobagyi G, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes. Journal Of Clinical Oncology 2007, 25: 586-586. DOI: 10.1200/jco.2007.25.18_suppl.586.Peer-Reviewed Original ResearchClinical responseTaxane sensitivityPreoperative therapyPrognostic factorsHER2 tumorsProspective studyBreast cancerDocetaxel/capecitabineDocetaxel/doxorubicinTaxane-containing regimensLarge prospective studiesPrimary breast cancerClinical prognostic factorsHER2- breast cancerNovel predictive markerCyclin-dependent kinase 1Breast tumor responseLogistic regression modelsEvaluable ptsAdjuvant therapyClinical outcomesPreclinical findingsPredictive markerTumor responseHER2 overexpression